Federal Mandate: Unifying AI Validation for Patient Safety

The rapid integration of artificial intelligence into diagnostic tools promises far-reaching advancements in healthcare, yet the fragmented field of validation protocols for these sophisticated models introduces a critical vulnerability. This variability in clinical performance not only poses significant risks to patient safety but also erodes the market trust essential for sustained innovation. Our official policy recommendation is clear: federal agencies must establish unified testing benchmarks to secure the future of diagnostic AI.

The Clinical Imperative for Standardized Validation

The promise of diagnostic AI, from enhanced imaging analysis to predictive analytics, is undeniable. However, without a strong, standardized framework for validating these models, their real-world efficacy and safety remain inconsistently assured. The core issue lies in the diverse methodologies currently employed by developers to demonstrate a model’s clinical utility and performance. This lack of uniformity makes it exceedingly difficult for healthcare providers, payers, and in the end, patients, to reliably assess the quality and trustworthiness of an AI-powered diagnostic. Consider the challenge of algorithmic drift, where an AI model’s performance degrades over time as real-world data distributions shift away from its training data. Without standardized, continuous monitoring and re-validation protocols, a diagnostic AI cleared today could become unreliable tomorrow, leading to misdiagnoses or delayed treatment. This shows the urgent need for a cohesive federal strategy that mandates consistent, rigorous validation from development through deployment and ongoing maintenance.

Working through Inconsistent Standards: Lessons from Tempus AI and PathAI

The experiences of leading diagnostic AI companies like Tempus AI and PathAI vividly illustrate the complexities and inconsistencies inherent in the current regulatory environment, particularly concerning Laboratory Developed Tests (LDTs). Both companies operate at the forefront of AI-driven diagnostics, developing sophisticated tools that analyze vast datasets to inform treatment decisions. Tempus AI, for instance, leverages large-scale genomic and clinical datasets to power its AI models, which assist in cancer care by identifying optimal therapies. PathAI focuses on digital pathology, using AI to improve the accuracy and efficiency of cancer diagnosis. Their respective journeys highlight the patchwork of validation requirements they must navigate. While the FDA has historically exercised enforcement discretion over LDTs, the field is rapidly changing. The FDA’s LDT Final Rule, which was published in May 2024 and aimed to bring LDTs under more consistent regulatory oversight, including premarket review, was officially rescinded in September 2025 following a federal court ruling. The FDA has since reverted to its policy of enforcement discretion over LDTs, meaning laboratories are generally not required to seek FDA clearance or approval for these tests. This regulatory reversal significantly impacts how companies like Tempus AI and PathAI validate and market their diagnostic offerings, leaving a continued need for standardized validation in this area. Before the LDT Final Rule, the validation of LDTs often fell under the purview of CLIA (Clinical Laboratory Improvement Amendments) regulations, which primarily focus on laboratory quality and analytical validity, rather than complete clinical validation of the diagnostic performance of novel AI algorithms. This distinction created a regulatory gap where the analytical rigor of an AI-powered LDT might be assessed, but its clinical utility and the potential for algorithmic bias or drift were less consistently scrutinized by a central authority. The evolving regulatory environment means that companies must adapt to shifting expectations. While some AI-powered diagnostics may pursue 510(k) clearance or even De Novo classification, many advanced LDTs have existed in a grey area. The upcoming changes will demand a more harmonized approach to validation, compelling developers to meet more stringent and standardized clinical performance benchmarks. FDA LDT Final Rule implementation timeline

The Executive Order on AI: A Mandate for Unified Validation

The White House’s Executive Order on Safe, Secure, and Trustworthy Artificial Intelligence, issued in late 2023, initially represented a key moment for AI regulation, with directives that had deep implications for diagnostic AI. That Executive Order mandated that federal agencies develop guidelines and best practices for the safe and responsible development and deployment of AI, including requirements for validation and testing. However, subsequent Executive Orders from the current administration, such as the Executive Order on Advanced AI Innovation and Security issued in June 2026, have shifted the federal focus towards voluntary frameworks for AI development and cybersecurity, explicitly stating that mandatory licensing or preclearance for new AI models is not authorized. This evolving field highlights the continued, and perhaps even more urgent, need for federal agencies to accelerate the development of unified benchmarks for diagnostic AI. Dr. Heidi Overton, nominated to be the next Commissioner of the FDA, and Acting Commissioner Kyle Diamantas, have both articulated the agency’s commitment to ensuring the safety and effectiveness of AI in healthcare, emphasizing the need for strong evidence generation. The Executive Order provides the impetus for the FDA, in collaboration with other agencies like the National Institutes of Health (NIH), to accelerate the development of these much-needed unified benchmarks. White House Executive Order on Safe, Secure, and Trustworthy AI The intersection of the FDA’s LDT Final Rule and the AI Executive Order creates a powerful mandate for change. While the LDT rule addresses the regulatory pathway for certain diagnostic tests, the Executive Order provides the overarching framework for ensuring the trustworthiness of all AI systems, including those used in diagnostics. This dual pressure makes the current moment ripe for the establishment of a complete, federal validation framework for diagnostic AI.

Recommendations for a Unified Federal Validation Framework

To address the current fragmentation and ensure the safety and efficacy of diagnostic AI, we propose the following policy recommendations for federal agencies:

• Establish a Multi-Agency Task Force: A collaborative body, perhaps led by the FDA with significant input from the NIH and other relevant stakeholders, should be formed to develop and continuously update a unified validation framework for diagnostic AI models. This task force would be responsible for defining key performance metrics, acceptable thresholds for bias, and standards for real-world evidence generation.
• Mandate Pre-Market and Post-Market Validation Standards: The framework must clearly delineate requirements for both pre-market validation (e.g., rigorous clinical trial design, diverse and representative training data) and strong post-market surveillance. The latter is important for monitoring algorithmic drift and ensuring ongoing performance in varied clinical settings. This includes defining clear protocols for adaptive AI models that learn and evolve over time, potentially using Predetermined Change Control Plans (PCCPs) to manage modifications without requiring entirely new premarket submissions for every minor update.
• Develop Standardized Test Datasets and Benchmarks: Federal agencies should facilitate the creation of publicly accessible, high-quality, and diverse standardized datasets to be used for benchmarking diagnostic AI models. This would allow for objective comparison of different models and help identify areas of underperformance or bias.
• Promote Transparency and Explainability: The framework should encourage, and where appropriate, mandate, greater transparency in AI model development and decision-making processes. This includes requirements for clear documentation of training data, model architecture, and the rationale behind diagnostic outputs. While full explainability can be challenging for complex neural networks, efforts towards interpretability are vital for clinical trust and accountability.
• Integrate GMLP Principles: The ten guiding principles of Good Machine Learning Practice (GMLP), developed by the FDA, Health Canada, and the MHRA, should be formally integrated into any federal validation framework. These principles provide a strong foundation for ensuring the quality, reliability, and safety of AI/ML medical devices throughout their lifecycle.
• Harmonize with International Standards: Recognizing the global nature of AI development, federal agencies should actively engage with international bodies to harmonize validation protocols, reducing regulatory burden for developers and facilitating broader access to safe and effective diagnostic AI. By proactively establishing these unified standards, federal agencies can foster an environment where innovation in diagnostic AI flourishes responsibly. This will not only protect patients from the risks of unvalidated or poorly performing models but also build the essential trust required for widespread adoption and investment in this far-reaching technology. The ECRI hazard rankings for 2026 and the AMA’s legislative activity surrounding AI in healthcare underscore the growing awareness of these risks and the urgent need for a coordinated federal response. ECRI 2026 Top 10 Health Technology Hazards
  

  Methodology and Source Note

This analysis synthesizes current federal directives, including the FDA’s evolving stance on LDTs and the complete mandates of the Executive Order on Safe, Secure, and Trustworthy AI. Our recommendations are grounded in the recognition that a fragmented regulatory field for diagnostic AI models poses significant risks to public health and hinders the responsible advancement of healthcare technology. The insights from leading developers like Tempus AI and PathAI further reinforce the practical challenges of working through inconsistent validation requirements, underscoring the critical need for a unified federal approach.